Consulting Agreement by and between Cyclacel Pharmaceuticals, Inc. and Brian Schwartz, M.D., dated January 26, 2024
Exhibit 10.13
CONSULTING AGREEMENT
This Consulting Agreement (“Agreement”) is made and entered into as of January 26, 2024 (“Effective Date”) by and between Cyclacel Limited (“Company”), with its registered office at 2 London Wall Place, London, EC2Y 5AU, United Kingdom and Brian Schwartz, MD, (“Consultant”), an individual residing at 465 NE 6th Street, Boca Raton, FL 33432, United States of America.
Both the Company and Consultant are referred to herein, individually, as a “Party” and, collectively, as the “Parties”.
WHEREAS, Company desires to retain Consultant to render consulting services as interim Chief Medical Officer to Company and Consultant desires to be so retained by Company and to perform such services further specified herein, all in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the premises, conditions and representations set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Company and Consultant, Company and Consultant agree as follows.
1. | PROFESSIONAL SERVICES |
1.3 | Location and Access. The consulting services shall be performed at Consultant’s |
premises or such other premises that Company and Consultant may mutually agree upon.
2. | PAYMENT |
The Company agrees to compensate Consultant for the services performed by Consultant pursuant to this Agreement in accordance with the payment terms set forth in Exhibit A, which is attached hereto and incorporated herein by reference. Payment will be made only for work that has been performed to the reasonable satisfaction of the Company.
3. | CONFIDENTIAL INFORMATION |
4. | OWNERSHIP OF WORK PRODUCT |
2
under his direction or jointly with others, which arise from or in connection with this Agreement (“Data and Inventions”). All work products hereunder shall be “work for hire” and Consultant shall have no interest in the Data and Inventions.
5. | CONSULTANT REPRESENTATION, WARRANTIES AND CERTAIN COVENANTS |
Consultant represents, warrants and covenants to the Company throughout the Term as follows.
6. | SOLICITATION OF COMPANY EMPLOYEES |
Consultant agrees that during the Term and for a period of twelve (12) months thereafter,
Consultant shall not, without Company’s prior written consent, recruit, solicit, or hire any employee
3
of the Company, or induce or attempt to induce any employee of the Company to discontinue his or her employment relationship with the Company.
7. | TERM AND TERMINATION |
7.1 | Term. This Agreement shall be effective for the period set forth in Exhibit A |
hereof (the “Term”).
If to Company: Cyclacel Limited 2 London Wall Place London EC2Y 5AU, U.K. Attn: EVP, Finance & COO Email: ***@*** With a copy to: Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 United States of America Attn: President & Chief Executive Officer Email: ***@*** | If to Consultant: Brian Schwartz, MD 465 NE 6th Street Boca Raton, FL 33432 United States of America Email: ***@*** |
8. | NOTICES |
Any notice or approval required or permitted under this Agreement will be delivered in writing and will be sent by (i) electronic mail or (ii) by overnight courier or, if the delivery is international, by two-day courier to the address specified below or to any other address that may be designated by prior notice. Any notice or approval delivered by electronic mail will be deemed to have been delivered the day it is sent, unless it arrives after 5:00 p.m. at the recipient address or on a day other
4
than a business day at the recipient address, in which case it shall be deemed delivered on the next business day. Any notice or approval sent by courier will be deemed delivered on the next business day after its date of posting if domestic or two business days after the day of posting if international.
9. | GENERAL |
5
IN WITNESS WHEREOF, the Parties the parties hereto have executed this Consulting Agreement on the Effective Date written above.
CYCLACEL LIMITED | | CONSULTANT | ||
| | | | |
| | | | |
By: | | By: | ||
| Paul McBarron | | | Brian Schwartz, MD |
| EVP, Finance & COO | | | |
6
Exhibit A
1. | Services. |
As part time interim Chief Medical Officer Consultant shall provide clinical, preclinical and drug development expertise in support of Cyclacel’s clinical development programs.
Consultant shall report to the President & CEO.
2. | Term. |
This Agreement shall be effective for the period (the “Term”) beginning on the Effective Date and shall continue in full force for 6 months (the “Term”), unless terminated by either Party as per the terms set out in Section 7 of this Agreement.
3. | Fees. |
For time spent by Consultant on providing consulting services requested by the Company the Consultant shall receive a) a grant of 12,500 options over common shares of the Company and 12,500 restricted stock units (RSUs) upon signature of this Agreement which will vest on a monthly basis during the six months starting with the commencement of the consultancy and b) additional grants awarded at the discretion of the Compensation Committee of the Board of Directors on a periodic basis during the Term.
4. | Payment Terms |
Consultant shall invoice Company on a regularly monthly basis for all work performed pursuant to this Agreement. Each invoice must set forth the subject of the work. Company will reimburse Consultant for any reasonable, authorized travel, lodging and other out-of-pocket expenses incurred by Consultant in the course of performing the Services hereunder, provided that Consultant furnishes Company with specific documentation therefor and the Company approves all such expenses in advance in writing.
All invoices shall be submitted directly to the Company, Accounts Payable Department, with an email address of ***@***. Payment of all undisputed amounts shall be made within forty-five (45) days after receipt of invoice by Company. If the Company has a dispute with any charges set forth in an invoice, Company shall notify Consultant of the dispute and provide Consultant details of the dispute. The Parties shall negotiate in good faith to promptly resolve disputes related to any invoiced amounts. Consultant shall maintain records of all time and expenses under this Agreement and shall provide Company reasonable access to the same upon request.
A-1